Please wait a minute...

Frontiers of Medicine

Front Med Chin    2010, Vol. 4 Issue (3) : 317-322     DOI: 10.1007/s11684-010-0035-4
RESEARCH ARTICLE |
Effect of salvia miltiorrhiza pretreatment on the CCK and VIP expression in hepatic ischemia-reperfusion-induced digestive tract congestion
Zhi-Yong ZHANG1, Xiao-Ping CHEN1, Qi-Ping LU2()
1. Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2. Department of General Surgery, Wuhan General Hospital of PLA, Wuhan 430070, China
Download: PDF(293 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

The inhibitory effect of different reperfusion periods 45 min following hepatic ischemia on the expression of cholecystokinin (CCK) and vasoactive intestinal peptide (VIP) in the jejunum and the effect of salvia miltiorrhiza pretreatment were investigated, and the possible mechanism and implications were explored. Eighty rats were randomly divided into four groups: normal control group (CO group), sham-operated group (SO group), ischemia/reperfusion (I/R) injury group (IR group) and salvia miltiorrhiza pretreatment group (SM group). The rat model of I/R was established by using a non-invasive artery clamp to clip (45 min) or relax the hepatic pedicle. In the SM group, saline (40 mL/kg) and salvia miltiorrhiza injection (6 g/kg) were injected via the tail vein 30 min before clipping the hepatic pedicle. In the SO group only the porta hepatis was dissected after laparotomy without clamping the hepatic pedicle. At 0, 3, 12, 24 and 72 h post-reperfusion, respectively, upper jejunum samples were taken for immunohistochemistry of CCK and VIP. It was found that 0 h after I/R, the expression of CCK and VIP in the upper jejunum was upregulated. With prolongation of the reperfusion period, the expression of CCK and VIP was also increased, reached the peak at the 24th h, and gradually returned to the normal level at the 72nd h after reperfusion. The levels of both CCK and VIP in the SM group were lower than those in the IR group. It is suggested that the digestive tract congestion injury caused by liver ischemia can upregulate the expression of CCK and VIP in the jejunum following reperfusion. Salviae pretreatment can partly reduce the increased expression of CCK and VIP in the jejunum in the same period, which might contribute to the early recovery of gastrointestinal motility.

Keywords hepatic ischemia-reperfusion      digestive tract congestion      cholecystokinin      vasoactive intestinal peptide      salvia miltiorrhiza     
Corresponding Authors: LU Qi-Ping,Email:ptwkzzy@yahoo.com.cn   
Issue Date: 05 September 2010
 Cite this article:   
Zhi-Yong ZHANG,Xiao-Ping CHEN,Qi-Ping LU. Effect of salvia miltiorrhiza pretreatment on the CCK and VIP expression in hepatic ischemia-reperfusion-induced digestive tract congestion[J]. Front Med Chin, 2010, 4(3): 317-322.
 URL:  
http://journal.hep.com.cn/fmd/EN/10.1007/s11684-010-0035-4
http://journal.hep.com.cn/fmd/EN/Y2010/V4/I3/317
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Zhi-Yong ZHANG
Xiao-Ping CHEN
Qi-Ping LU
groups0 h3 h12 h24 h72 hF valuesP values
CO20.37±0.9620.94±1.1920.87±1.0020.86±1.2920.76±1.070.410.80
SO20.72±1.3020.35±1.3420.65±1.5320.81±1.1920.59±1.380.160.96
IR25.53±1.00*#31.58±1.07*#40.54±1.30*#47.21±0.85*#22.55±0.84*#1013.720.00
SM22.95±0.86*27.20±0.86*35.21±0.52*41.16±0.79*21.24±0.871137.580.00
F values52.23225.55770.331700.986.99
P values0.000.000.000.000.00
Tab.1  The positive number of units of CCK expression in jejunum tissues at different reperfusion time limit points 45 min following hepatic ischemia
Fig.1  The CCK expression at 24 h of reperfusion in normal control group (a), sham-operated group (b), ischemia/reperfusion (I/R) injury group (c) and salvia miltiorrhiza pretreatment group (d) (× 400). CCK: cholecystokinin.
groups0 h3 h12 h24 h72 hF valuesP values
CO19.12±1.1718.64±0.6318.75±0.6019.01±0.7618.56±0.880.890.47
SO18.76±0.8918.58±0.5718.43±0.6618.14±1.0418.51±1.120.680.61
IR26.10±1.35*#32.35±1.34*#38.40±1.27*#46.01±1.03*#23.05±1.32*#535.340.00
SM22.43±0.88*25.97±0.90*35.15±1.04*41.58±0.87*21.52±0.71*968.520.00
F values98.29526.221281.582476.2247.38
P value0.000.000.000.000.00
Tab.2  The positive number of units of VIP expression in jejunum tissues at different reperfusion time limit points 45 min following hepatic ischemia
Fig.2  The VIP expression at 24 h of reperfusion in the normal control group (a), sham-operated group (b), ischemia/reperfusion (I/R) injury group (c) and salvia miltiorrhiza pretreatment group (d) (× 400). VIP: vasoactive intestinal peptide.
1 Liu Y P, Liu J S. The progress of mechanism of liver ischemia-reperfusion. Linchuang Yanjiu Zazhi , 2008, 25(10): 1904–1907 (in Chinese)
2 Devey L, Ferenbach D, Mohr E, Sangster K, Bellamy C O, Hughes J, Wigmore S J. Tissue-resident macrophages protect the liver from ischemia reperfusion injury via a heme oxygenase-1-dependent mechanism. Mol Ther , 2009, 17(1): 65–72
doi: 10.1038/mt.2008.237
3 Tsung A, Klune J R, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz D B, Geller D A, Rosengart M R, Billiar T R. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med , 2007, 204(12): 2913–2923
doi: 10.1084/jem.20070247
4 Zhong Z, Ramshesh V K, Rehman H, Currin R T, Sridharan V, Theruvath T P, Kim I, Wright G L, Lemasters J J. Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol , 2008, 295(4): G823–G832
doi: 10.1152/ajpgi.90287.2008
5 Vardanian A J, Busuttil R W, Kupiec-Weglinski J W. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med , 2008, 14(5–6): 337–345
6 Fu R, Shen H. A technical study on C-mean clustering segmentation for color immunohistochemical image based on matlab. Zhongguo Tishixue Yu Tuxiang Fenxi , 2007, 12(1): 6–10 (in Chinese)
7 Zhang N, Tao K, Huang T. Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29. J Huazhong Univ Sci Technolog Med Sci , 2007, 27(4): 399–402
doi: 10.1007/s11596-007-0412-7
8 Wan C, Wang H, Cheng R, Gou S, Liu T. Effect of target-directed regulation of uncoupling protein-2 gene expression on ischemia-reperfusion injury of hepatocytes. J Huazhong Univ Sci Technol Med Sci , 2008, 28(5): 558–563
9 Chen J, Wang G. Role of nuclear factor kappaB in intestine injury induced by hepatic ischemia reperfusion. J Huazhong Univ Sci Technol Med Sci , 2004, 24(3): 284–285 , 291
10 Zhang J, Wu H, Wang L, Zhang J, Wang H, Zheng Q. TLR2 mRNA upregulation in ischemic lobes in mouse partial hepatic ischemia/reperfusion injury model. J Huazhong Univ Sci Technol Med Sci , 2004, 24(2): 144–146
11 Huang C, Zhang Z, Qiu F. Effects of 2-APB on store-operated Ca2+ channel currents of hepatocytes after hepatic ischemia/reperfusion injury in rats. J Huazhong Univ Sci Technol Med Sci , 2005, 25(1): 39–41
12 Cai H, Guang Y, Liu L. The protective effects of in vitro cultivated calculus bovis on the cerebral and myocardial cells in hypoxic mice. J Huazhong Univ Sci Technol Med Sci , 2007, 27(6): 635–638
13 D'Alessio D. Intestinal hormones and regulation of satiety: the case for CCK, GLP-1, PYY, and Apo A-IV. JPEN , 2008, 32(5): 567–568
14 Raybould H E. Mechanisms of CCK signaling from gut to brain. Curr Opin Pharmacol , 2007, 7(6): 570–574
doi: 10.1016/j.coph.2007.09.006
15 Berna M J, Jensen R T. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem , 2007, 7(12): 1211–1231
doi: 10.2174/156802607780960519
16 Miller L J, Gao F. Structural basis of cholecystokinin receptor binding and regulation. Pharmacol Ther , 2008, 119(1): 83–95
doi: 10.1016/j.pharmthera.2008.05.001
17 Bai J, Lü Y, Bai Q. Construction of porcine CCK pDNA and its expression in COS-7 cells. J Huazhong Univ Sci Technol Med Sci , 2007, 27(3): 278–280
doi: 10.1007/s11596-007-0315-7
18 Tang M, Ni H, Xu L. Changes in the mRNA concentration of preprocholecystokinin in rat cerebral cortex and hippocampus after gastric distension. Acta Physiologica Sinica , 1999, 51(5): 488–494
19 Onoue S, Misaka S, Yamada S. Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn Schmiedebergs Arch Pharmacol , 2008, 377(4–6): 579–590
doi: 10.1007/s00210-007-0232-0
20 Masmoudi-Kouki O, Gandolfo P, Castel H, Leprince J, Fournier A, Dejda A, Vaudry H, Tonon M C. Role of PACAP and VIP in astroglial functions. Peptides , 2007, 28(9): 1753–1760
doi: 10.1016/j.peptides.2007.05.015
21 Watanabe S. Vasoactive intestinal polypeptide (VIP). Nippon Rinsho , 2005, 63(Suppl 8): 502–504
22 Reich A, Szepietowski J C. Vasoactive peptides in the pathogenesis of psoriasis. G Ital Dermatol Venereol , 2008, 143(5): 289–298
23 Yoshiyama M, de Groat W C. The role of vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide in the neural pathways controlling the lower urinary tract. J Mol Neurosci , 2008, 36(1–3): 227–240
doi: 10.1007/s12031-008-9090-6
24 Langer I, Robberecht P. Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors. Biochem Soc Trans , 2007, 35(Pt 4): 724–728
25 Gong S, Ding J, Chang Q. The expression of VIP and SP in the cochlea of spontaneously hypertensive rats and its implication. J Huazhong Univ Sci Technol Med Sci , 2004, 24(4): 396–399
26 Muller J M, Philippe M, Chevrier L, Héraud C, Alleaume C, Chadéneau C. The VIP-receptor system in neuroblastoma cells. Regul Pept , 2006, 137(1–2): 34–41
doi: 10.1016/j.regpep.2006.06.014
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed